Search for more clinical trials
The Serum Tissue Factor Level in Lung Cancer Patients as a Prognostic Factor
Conditions
Lung Cancer
Conditions: official terms
Lung Neoplasms
Conditions: Keywords
Tissue factor, Lung cancer, Tissue factor protein inhibitor, Factor VII, Factor X
Study Type
Observational
Study Phase
N/A
Study Design
Allocation: Random Sample, Observational Model: Natural History, Time Perspective: Cross-Sectional
Overall Status
Recruiting
Summary
This study uses serum tissue factor and tissue factor inhibitor and factor VII to monitor the pre-coagulation status in lung cancer patients and to correlate the pre-coagulation status with clinical staging and prognosis.
Detailed Description
The staging of lung cancer was according to tumor size, involvement of lymph node and metastatic status. But there is a different prognosis in cancer patients of the same stage. The coagulation status of cancer patients was considered as an important possible prognostic factor. So in this study, we want to evaluate patients' coagulation status and find the relation of coagulation status and cancer status.
We thus propose a prospective study using coagulation factors in order to search for the relationship between cancer stage and pre-coagulation status in Taiwanese lung cancer patients. We will also evaluate the potential use of tissue factor as a prognosis predictor in lung cancer patients.
We thus propose a prospective study using coagulation factors in order to search for the relationship between cancer stage and pre-coagulation status in Taiwanese lung cancer patients. We will also evaluate the potential use of tissue factor as a prognosis predictor in lung cancer patients.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 16 Years
Gender: Both
Criteria: Inclusion Criteria:
- Patients with newly-diagnosed lung cancer
- Serum from cancer-free healthy volunteers
Exclusion Criteria:
- Chronic renal failure or end-stage renal disease [ESRD] (creatinine [Cr] > 2 )
- Hyperlipidemia on statin therapy
- Acute myocardial infarction
- Tapal or Plavix use
- Active thromboembolic event
- Severe liver disease (> child B)
- Patients with newly-diagnosed lung cancer
- Serum from cancer-free healthy volunteers
Exclusion Criteria:
- Chronic renal failure or end-stage renal disease [ESRD] (creatinine [Cr] > 2 )
- Hyperlipidemia on statin therapy
- Acute myocardial infarction
- Tapal or Plavix use
- Active thromboembolic event
- Severe liver disease (> child B)
Location
National Taiwan University Hospital
Taipei, Taiwan
Status: Recruiting
Contact: Chong-Jen Yu, M.D., Ph.D. - 886-2-2356-2905
Start Date
June 2005
Sponsors
National Taiwan University Hospital
Source
National Taiwan University Hospital
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page